1. Home
  2. AYTU vs TRIB Comparison

AYTU vs TRIB Comparison

Compare AYTU & TRIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AYTU
  • TRIB
  • Stock Information
  • Founded
  • AYTU N/A
  • TRIB 1992
  • Country
  • AYTU United States
  • TRIB Ireland
  • Employees
  • AYTU N/A
  • TRIB N/A
  • Industry
  • AYTU Biotechnology: Pharmaceutical Preparations
  • TRIB Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • AYTU Health Care
  • TRIB Health Care
  • Exchange
  • AYTU Nasdaq
  • TRIB Nasdaq
  • Market Cap
  • AYTU 11.8M
  • TRIB 12.5M
  • IPO Year
  • AYTU N/A
  • TRIB N/A
  • Fundamental
  • Price
  • AYTU $2.00
  • TRIB $0.65
  • Analyst Decision
  • AYTU
  • TRIB
  • Analyst Count
  • AYTU 0
  • TRIB 0
  • Target Price
  • AYTU N/A
  • TRIB N/A
  • AVG Volume (30 Days)
  • AYTU 4.1M
  • TRIB 61.0K
  • Earning Date
  • AYTU 05-14-2025
  • TRIB 06-17-2025
  • Dividend Yield
  • AYTU N/A
  • TRIB N/A
  • EPS Growth
  • AYTU N/A
  • TRIB N/A
  • EPS
  • AYTU N/A
  • TRIB N/A
  • Revenue
  • AYTU $77,691,000.00
  • TRIB $61,555,000.00
  • Revenue This Year
  • AYTU N/A
  • TRIB $13.51
  • Revenue Next Year
  • AYTU $4.60
  • TRIB $13.14
  • P/E Ratio
  • AYTU N/A
  • TRIB N/A
  • Revenue Growth
  • AYTU N/A
  • TRIB 8.31
  • 52 Week Low
  • AYTU $0.95
  • TRIB $0.48
  • 52 Week High
  • AYTU $3.21
  • TRIB $3.55
  • Technical
  • Relative Strength Index (RSI)
  • AYTU 60.38
  • TRIB 42.17
  • Support Level
  • AYTU $1.46
  • TRIB $0.63
  • Resistance Level
  • AYTU $2.70
  • TRIB $0.68
  • Average True Range (ATR)
  • AYTU 0.17
  • TRIB 0.05
  • MACD
  • AYTU -0.04
  • TRIB -0.01
  • Stochastic Oscillator
  • AYTU 60.67
  • TRIB 7.77

About AYTU Aytu BioPharma Inc.

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

About TRIB Trinity Biotech plc

Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.

Share on Social Networks: